Once-Common Hysterectomy Technique Linked to Worse Uterine Cancer Outcomes
Every year, nearly 700,000 American women have surgery to remove their uterus (hysterectomy) or uterine fibroids (myomectomy). A laparoscopic surgical technique once commonly used in these procedures could be worsening the outcomes for women who have undiagnosed uterine cancer at the time of the procedure, Yale Cancer Center scientists report in the Journal of Clinical Oncology.
Doctors working on better HPV vaccination coverage for pre-teens and teens
The vaccine for Human Papilloma Virus, according to recent studies, is working better than expected, even though vaccination rates in both Connecticut and the country are stagnating well below the target rate. To increase those rates, health experts are recommending doctors urge parents to get the vaccine for their pre-teens and teenagers as part of a back-to-school checkup.
Alessandro Santin Recognized as 2019 ASCO Leader in Cancer Care
Research by Alessandro Santin, M.D., professor of gynecology, obstetrics & reproductive sciences and leader of the Disease Aligned Research Team of the Gynecologic Oncology Program at Smilow Cancer Hospital and Yale Cancer Center, has had his research selected as one of the top five advances of the year by the American Society of Clinical Oncology (ASCO).
Greenwich Hospital and the Town of Greenwich partner to announce a new program to screen earlier for Breast and Ovarian Cancers
Greenwich, CT (May 1, 2019) – Greenwich Hospital will launch a new physician education program to help all doctors recognize potential early signs of breast and ovarian cancer in an effort to diagnose both diseases much sooner. Called the MAT Education Program, the curriculum was developed by physicians at Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center at the behest of Greenwich resident Kaile Josephs Zagger who lost her mother, Marilyn Ann Trahan (MAT) 20 years ago to ovarian cancer.
Yale OBGYN Research Highlighted in ASCO's 14th Annual Report on Progress Against Cancer
Advance of the Year: Progress in Treating Rare Cancers This year, ASCO names Progress in Treating Rare Cancers as the Advance of the Year. In the United States, rare cancers account for approximately 20% of all cancers diagnosed each year, and incidence rates vary worldwide. Progress has historically lagged behind the achievements made in more common cancers; however, five major studies this past year offer significant steps forward, making this a notable year for advances in rare cancers. Research from the Yale School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences was selected as #4: Trastuzumab effective for a rare form of endometrial cancer.
Yale Cancer Center researchers find genetic explanations behind the rapid spread of ovarian cancer
In a breakthrough study, Yale Cancer Center (YCC) researchers have defined the genetic characteristics of primary, metastatic and recurrent ovarian tumors and evaluated new targeted therapies to treat the disease. The findings are reported today in the Proceedings of the National Academy of Science (PNAS) online early edition.
Smilow Gynecologic Oncology at Lawrence + Memorial
Elena Ratner, MD and Dan-Arin Silasi, MD, Gynecologic Oncologists at Smilow Cancer Hospital at Yale New Haven and Associate Professors of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine, have expanded their practice to care for women at Lawrence + Memorial Hospital and the Smilow Cancer Hospital Care Center in Waterford.
Does Trastuzumab Plus Carbo/Paclitaxel Up PFS in Advanced HER2+ Uterine Carcinoma?
The addition of trastuzumab to the combination of carboplatin and paclitaxel was well tolerated among women with advanced or recurrent uterine serous carcinoma (USC) tumors that overexpress the tyrosine kinase human epidermal growth factor receptor 2 (HER2/neu), according to findings from a randomized phase II trial presented at the 2018 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, held March 24–27 in New Orleans, Louisiana. “This encouraging result deserves further investigation to determine the impact of HER2/neu targeted treatment in overall survival in women with advanced or recurrent USC who overexpress HER2/neu,” said Alessandro D. Santin, MD, of the Yale University School of Medicine in New Haven, Connecticut.
Trastuzumab Active in Uterine Serous Carcinoma
Patients with HER2-positive uterine serous carcinoma (USC) had a greater than 50% improvement in progression-free survival (PFS) when treated with trastuzumab (Herceptin) and chemotherapy versus chemotherapy alone, a small randomized trial showed. The median PFS increased from 8.0 months with carboplatin and paclitaxel to 12.6 months with the addition of trastuzumab to the same chemotherapy regimen. Patients with more advanced disease had almost a twofold increase in median PFS from 9.3 months with chemotherapy to 17.9 months with chemotherapy plus trastuzumab.
A Critical Mission: Preserving Fertility
As Director of the Yale Fertility Center and Fertility Preservation Program, Dr. Patrizio is at Smilow with a mission: to raise awareness of fertility preservation options among Smilow’s patients and practitioners, and to make it more convenient for patients to incorporate those options into their treatment plans
Be Your Own Advocate
Mary Lynne Barber is no stranger to ovarian cancer. Her mother was diagnosed with stage IV ovarian cancer in her seventies and died from the disease six months later. After her mother’s death, Mary Lynne’s gynecologist ordered a CA 125 test, a blood test that measures the amount of the protein CA 125, which is found in greater concentration in tumor cells, particularly ovarian cancer cells. A higher level can indicate the presence of cancer, but there can also be several other causes. Mary Lynne’s CA 125 test was normal.